CY1118778T1 - Ανταγωνιστες υποδοχεα βραδυκινινης και φαρμακευτικες συνθεσεις οι οποιες περιεχουν αυτους - Google Patents

Ανταγωνιστες υποδοχεα βραδυκινινης και φαρμακευτικες συνθεσεις οι οποιες περιεχουν αυτους

Info

Publication number
CY1118778T1
CY1118778T1 CY20171100386T CY171100386T CY1118778T1 CY 1118778 T1 CY1118778 T1 CY 1118778T1 CY 20171100386 T CY20171100386 T CY 20171100386T CY 171100386 T CY171100386 T CY 171100386T CY 1118778 T1 CY1118778 T1 CY 1118778T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
radykinin
contain
competition
receptors
Prior art date
Application number
CY20171100386T
Other languages
English (en)
Inventor
Andrea Rosario Beccari
Gianluca Bianchini
Michela Fani’
Mara Zippoli
Chiara Liberati
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of CY1118778T1 publication Critical patent/CY1118778T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά νέες ενώσεις, την χρήση αυτών στην πρόληψη ή την αγωγή των συμπτωμάτων και διαταραχών οι οποίες σχετίζονται με το μονοπάτι Β1 της βραδυκινίνης και φαρμακευτικές συνθέσεις οι οποίες περιέχουν αυτές.
CY20171100386T 2013-06-14 2017-03-29 Ανταγωνιστες υποδοχεα βραδυκινινης και φαρμακευτικες συνθεσεις οι οποιες περιεχουν αυτους CY1118778T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13172137.5A EP2813502B1 (en) 2013-06-14 2013-06-14 Bradykinin receptor antagonists and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
CY1118778T1 true CY1118778T1 (el) 2017-07-12

Family

ID=48607169

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100386T CY1118778T1 (el) 2013-06-14 2017-03-29 Ανταγωνιστες υποδοχεα βραδυκινινης και φαρμακευτικες συνθεσεις οι οποιες περιεχουν αυτους

Country Status (13)

Country Link
US (1) US9409876B2 (el)
EP (1) EP2813502B1 (el)
CY (1) CY1118778T1 (el)
DK (1) DK2813502T3 (el)
ES (1) ES2621085T3 (el)
HR (1) HRP20170455T1 (el)
HU (1) HUE032179T2 (el)
LT (1) LT2813502T (el)
ME (1) ME02580B (el)
PL (1) PL2813502T3 (el)
PT (1) PT2813502T (el)
RS (1) RS55977B1 (el)
SI (1) SI2813502T1 (el)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006083A1 (en) 1994-08-24 1996-02-29 Pfizer Pharmaceuticals Inc. 2-(piperazinyl-1-carbonylmethyl)-1,4-dihydropyridines as bradykinin antagonists
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
WO2001005783A1 (en) * 1999-07-15 2001-01-25 Pharmacopeia, Inc. Bradykinin b1 receptor antagonists
AR035891A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de sulfonamida, un proceso para su produccion, su uso para la fabricacion de un medicamento para el tratamiento o la prevencion de una enfermedad o condicion en donde tenga un papel o este implicada de activacion del receptor de bradiquinina beta1, y composiciones farmaceuticas y combinaci
AU2002346048A1 (en) 2001-06-07 2002-12-16 Merck And Co., Inc. Benzodiazepine bradykinin antagonists
DE10134721A1 (de) 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
JP2005530753A (ja) 2002-05-03 2005-10-13 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンアンタゴニストとしてのスルホニルキノキサロンアセトアミド誘導体および関連化合物
FR2840897B1 (fr) 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
US20040034064A1 (en) 2002-08-06 2004-02-19 Kuduk Scott D. 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives
US20040029920A1 (en) 2002-08-06 2004-02-12 Kuduk Scott D. 2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives
US20040063761A1 (en) 2002-08-06 2004-04-01 Kuduk Scott D. 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives
US6908921B2 (en) 2002-12-13 2005-06-21 Merck & Co., Inc. Quinoxalinone derivatives as bradykinin B1 antagonists
US20060173023A1 (en) * 2005-02-01 2006-08-03 Wood Michael R 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation
TW201024279A (en) 2008-09-18 2010-07-01 Jerini Ag Use of B1 receptor antagonists

Also Published As

Publication number Publication date
HUE032179T2 (hu) 2017-09-28
LT2813502T (lt) 2017-03-10
ES2621085T3 (es) 2017-06-30
EP2813502B1 (en) 2017-01-04
HRP20170455T1 (hr) 2017-06-02
SI2813502T1 (sl) 2017-05-31
ME02580B (me) 2017-06-20
US9409876B2 (en) 2016-08-09
DK2813502T3 (en) 2017-02-27
PL2813502T3 (pl) 2017-06-30
US20140371274A1 (en) 2014-12-18
PT2813502T (pt) 2017-04-06
RS55977B1 (sr) 2017-09-29
EP2813502A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
CY1125436T1 (el) Αναστολεις dna-pk
CY1122631T1 (el) Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
CY1120452T1 (el) Παραγωγο αμιδιου πυραζολης
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201692109A1 (ru) Варианты антител к фактору d и их применение
CY1123194T1 (el) Νεες αντιβακτηριακες ενωσεις
CY1123465T1 (el) Αντιβακτηριακες ενωσεις ευρεως φασματος
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors